Sermorelin is a short chain of amino acids that stimulates the body's release of growth hormone. It has spent years in the gray zone of longevity clinics and compounding pharmacies, and as of November 2026 it is being sold at national telehealth scale, which makes it worth laying out what is actually documented about it and what is not.
What it is and how it is marketed
Sermorelin works by stimulating growth-hormone release, and it is marketed for recovery, body composition and anti-aging, according to CNBC's reporting on the compound. Those three marketing categories are doing a lot of work: none of them is a regulatory indication, and CNBC notes that the compounded formulations now being sold are not approved by the Food and Drug Administration.
Why it is suddenly available
The shift is regulatory, not scientific. The Health and Human Services Department issued a policy in October saying the FDA will not take enforcement action against licensed pharmacies, federal facilities or physicians that compound and dispense six unapproved peptides while formal rules are reviewed, which in practice opened the door without granting approval of the peptides themselves.
Where it is being sold now
Sermorelin is one of five compounded formulations in the Peptides+ platform Hims and Hers launched across the U.S., alongside NAD+, glutathione, vitamin B-12 and L-carnitine, with at-home blood collection and ongoing clinical oversight. More than 10,000 people signed up for the early access list within 15 days, a company spokesperson told CNBC.
What Isn't Established
Almost everything downstream of the mechanism. Hims chief medical officer Dr. Anant Vinjamoori told CNBC the company has more to learn about how best to use the peptides and how effective they are, saying "we don't have all of this data that we're used to having with compounds like this." Paul Knoepfler of UC Davis Health put the gap more bluntly: "the dosing for these products really has not been established." Joshua Kritzer of Tufts added that without large clinical trials, researchers cannot rule out rare but serious complications. Neither source cites a single human outcome trial on sermorelin.
The state of the evidence
There is a plausible mechanism, a regulatory opening, a distribution channel reaching millions, and no published efficacy data in either source. That is an unusual order of operations, and the company selling it says so itself.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.